COLORECTAL CANCER

COLORECTAL
CANCER (CRC)

  • 3rd most commonly diagnosed cancer worldwide
  • 1,849,518 new cases in 2018 worldwide
  • 2nd most lethal cancer worldwide
  • 880,792 deaths in 2018 worldwide
  • 67% of treated patients survive 5 years or more

CANNABICSĀ® RCC-33 DRUG CANDIDATE FOR TREATING COLORECTAL CANCER

  • A novel cannabinoid-based formulation
  • Formula demonstrated significant synergistic antitumor effect in pre clinical studies
  • None psychoactive formulation
  • Patent pending

CLINICAL PATH

  • Preclinical POC validation (ongoing)
  • Dossier preparation for submission of Pre-IND meeting request with FDA

EXPERIMENT GOAL

Evaluation of RCC-33 to prolongs survival rate on mice bearing xenografts of human colorectal adenocarcinoma.

SYNERGISTIC INTERACTION OF RCC-33
ON COLON CANCER CELL LINES